Drugs / [18F]PT2385
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04989959 | Aug 2021 → Aug 2026 overdue | clear cell renal carcinoma | Orhan Kemal Oz | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]PT2385 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04989959 ↗ |
| Modality | Diagnostic / imaging agent | “investigational imaging will evaluate HIF2α expression within a tumor type and across different tumor types.” NCT04989959 ↗ |
| Route | Intravenous | “by intravenous (IV) push” NCT04989959 ↗ |